We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Alnylam Presents Pre-Clinical Data on ALN-TTR for the Treatment of Transthyretin-Mediated Amyloidosis

News   Nov 03, 2009

 
Alnylam Presents Pre-Clinical Data on ALN-TTR for the Treatment of Transthyretin-Mediated Amyloidosis
 
 
 

RELATED ARTICLES

Why Do Our Immune Responses Differ?

News

A study of 1,000 individuals has identified three main factors that determine how our immune responses differ. The research might help identify ways to make better vaccines and improve our understanding of autoimmune disease.

READ MORE

Breast Cancers Enlist the Help of Normal Cells to Help Them Spread & Survive

News

Researchers have shown that triple negative breast tumours - which are the most aggressive and have the fewest treatment options - might one day be treated with a drug that cuts the 'phone lines' between normal cells and tumour cells.

READ MORE

Good Grip, Good Health

News

Measuring hand grip can help identify youths who could benefit from lifestyle changes, says new research. While other studies have shown that muscle weakness as measured by grip strength is a predictor of unhealthy outcomes - including cardiovascular and metabolic diseases - this is the first to do so for adolescent health over time.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE